Применение фитопрепаратов на основе терпенов при мочекаменной болезни
Автор: Сивков А.В., Черепанова Е.В., Шадеркина В.А.
Журнал: Экспериментальная и клиническая урология @ecuro
Рубрика: Клинические исследования
Статья в выпуске: 1, 2011 года.
Бесплатный доступ
Мочекаменная болезнь, лечение, фитопрепараты, роватинекс
Короткий адрес: https://sciup.org/142188263
IDR: 142188263
The use of herbal ingrediends on the basis of terpenes in the treatment of urolithiasis
One of the common urological diseases is urolithiasis. Various groups of drugs are used for concrements delivery. Herbal medicine (essential oils and / or terpenes) has long been used in the treatment of urolithiasis. One of the drugs, which is based on a special combination of terpenes, is Rowatinex having a triple action: lithollitic, spasmolytic and diuretic. The first clinical and preclinical trials with Rowatinex occurred between 1954-1956 yrs. Since that time is has been actively used in the treatment of urolithiasis in many countries around the world. The indications for Rowatinex are: prevention of kidney stone disease, relapse prevention stone formation, conservative treatment of kidney stones, renal colic, chronic urinary tract infection. The article provides an experience of clinical use of Rowatinex in Russian institute of Urology (Moscow) and Barnaul Medical University. The study included 30 patients with various forms of urolithiasis. Inclusion criteria were: patient age from 18 to 80 years, the presence of kidney or ureter stones, the presence of small kidney stones, chronic pyelonephritis. 15 patients received Rowatinex, 15 - were in the control group. Repeated study was performed in 18-20 days. While taking the drug the elimination of small fragments of stones was noted in 73% vs 32% in the control group. The complete stone-free rate was achieved in 67% taking the drug versus 24% in the control group. The researchers confirmed the clinical efficacy Rowatinex for the treatment of patients with stones in the kidney and ureter.
Список литературы Применение фитопрепаратов на основе терпенов при мочекаменной болезни
- Аполихин О.И., Сивков А.В, Бешлиев Д.А., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости в Российской Федерации по данным официальной статистики//Экспериментальная и клиническая урология. 2010. № 1. С. 4-11.
- Черепанова Е.В., Дзеранов Н.К. Метафилактика мочекаменной болезни в амбулаторных условиях//Экспериментальная и клиническая урология. 2010. №3. С. 33-39.
- Healy K.A., Ogan K. Nonsurgical management of urolithiasis: an overview of expulsive therapy//J. Endourol. 2005. Vol. 19. № 7. P. 759-767.
- Sybilska D., Asztemborska M. Chiral recognition of terpenoids in some pharmaceuticals derived from natural sources//J. Biochem Biophys Methods. 2002. Vol. 54. № 1-3. P. 187-195.
- Greenwood D., Johnson N., Eley A., Slack R.C., Bell G.D. The antibacterial activity of Rowatinex//J. Antimicrob Chemother. 1982. Vol. 10. № 6. P. 549-551.
- Kanstein K. Clinical experiences with new terpene containing drugs//Med. Monatsschr. 1956. Vol. 10. № 4. P. 254-257.
- Браун И. Наши наблюдения над лечением больных Роватинексом//Урология. 1959. № 3. С. 65-66.
- Yamamoto I., Korai Y., Nakamura T. Clinical use of rowatinex in urolithiasis//Nippon Hinyokika Gakkai Zasshi. 1963. Vol. 54. P.753-757.
- Bard R. On the role of ethereal oils in prevention of renal calculi: experiences with the use of rowatinex//Magy Seb. 1961. Vol. 14. P. 203-206.
- Geinitz W. Animal experiments on urinary calculus prevention//Munch Med Wochenschr. 1956. Vol. 98. №26. P. 895-897.
- Basagic E., Gasparovic I. Nephrocalcinosis in rats//Urol. 1962. Vol. 55. P. 7-10.
- Stern P., Vukcevic S. On the alteration of nephrocalcinosis in the rat//Urol. 1960. Vol. 53. P. 59-63.
- Chromatographic studies of the enantiomeric composition of some therapeutic compositions applied in the treatment of liver and kidney diseases/Sybilska D., Kowalczyk J., Asztemborska M., Ochocka RJ, Lamparczyk H.//J Chromatogr A. 1994. Vol. 665. № 1. P. 67-73.
- Engelstein D., Kahan E., Servadio C. Rowatinex for the treatment of ureterolithiasis//J. Urol. 1992. Vol. 98. № 2. P. 98-100.
- Mukamel E., Engelstein D., Simon D., Servadio C. The value of Rowatinex in the treatment of ureterolithiasis//J. Urol. 1987. Vol. 93. № 1. P. 31-33.
- Romics I., Siller G., Kohnen R., Mavrogenis S., Varga J., Holman E. A special terpene combination (rowatinex®) improves stone clearance after extracorporeal shockwave lithotripsy in urolithiasis patients: results of a placebo-controlled randomised controlled trial///Urol Int. 2011. Vol. 86. № 1. P. 102-109.
- Djaladat H., Mahouri K., Khalifeh Shooshtary F., Ahmadieh A. Effect of Rowatinex on calculus clearance after extracorporeal shock wave lithotripsy//Urol. J. 2009. Vol. 6. № 1. P. 9-13.
- Pricop C., Novac C., Negru D., Ilie C., Pricop A., Tănase V. Can selective alphablockers help the spontaneous passage of the stones located in the uretero-bladder junction?//Rev Med Chir Soc Med Nat Iasi. 2004. Vol. 108. № 1. P.128-133.
- Aldemir M., Ucgul Y.E., Kayıgil O. Evaluation of the efficiency of tamsulosin and Rowatinex in patients with distal ureteral stones: a prospective, randomized, controlled study//Int Urol Nephrol. 2010. Vol. 42. № 2. P. 325-330.
- Джавад-Заде С.М. Мочекаменная болезнь в эпидемическом регионе: этиопатогенез, клиника, лечение: автореф. дис. д-ра мед. Наук. М. 1997. 26 с.
